Medarex Reports Phase 1/2 Clinical Data Of MDX-060 In Lymphoma At American Association For Cancer Research Meeting

Medarex, Inc. (Nasdaq: MEDX) announced data from a Phase 1/2 trial that suggest a potential association between higher doses of MDX-060, an investigational anti-CD30 antibody, and improvement in disease control and prolonged progression-free survival in patients with relapsed or refractory CD30- positive lymphomas.

More: continued here

Filed under: Clinical Trials on April 17th, 2008